1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,194 | 0,206 | 06.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | VIVA BIOTECH (01873): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO CONNECTED TRANSACTION | - | HKEx | ||
| 30.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 28.05. | VIVA BIOTECH (01873): CONNECTED TRANSACTION INVESTMENT IN LIMITED PARTNERSHIP FUND | 1 | HKEx | ||
| 15.05. | Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery | 262 | PR Newswire | SHANGHAI, May 15, 2025 /PRNewswire/ -- On May 13, 2025, Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive... ► Artikel lesen | |
| 06.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 24.04. | VIVA BIOTECH (01873): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): PROPOSED RE-ELECTION OF RETIRING DIRECTORS PROPOSED RE-APPOINTMENT OF AUDITOR PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE ... | - | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): 2024 ANNUAL REPORT | - | HKEx | ||
| 07.04. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 28.03. | Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection | 314 | PR Newswire | SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings... ► Artikel lesen | |
| 27.03. | Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D | 109 | PR Newswire | Highlights of Annual Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded... ► Artikel lesen | |
| 27.03. | VIVA BIOTECH (01873): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 27.03. | VIVA BIOTECH (01873): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | - | HKEx | ||
| 27.03. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 27.03. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT ON THE PASSING OF U.S. FDA ON-SITE INSPECTION BY LANGHUA PHARMACEUTICAL, A WHOLLY-OWNED SUBSIDIARY | 1 | HKEx | ||
| 27.03. | VIVA BIOTECH (01873): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 AND CHANGE OF COMPOSITION OF THE NOMINATION COMMITTEE | 3 | HKEx | ||
| 17.03. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 1 | HKEx | ||
| 13.03. | VIVA BIOTECH (01873): POSITIVE PROFIT ALERT | 2 | HKEx |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,732 | -0,15 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH 03.06.2025 / 14:27 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group. Für den... ► Artikel lesen | |
| NOVONESIS | 64,32 | +0,22 % | dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion | Press Release
dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion
Kaiseraugst (Switzerland), Maastricht (Netherlands), June 2, 2025
dsm-firmenich... ► Artikel lesen | |
| GENMAB | 193,95 | -0,69 % | Genmab A/S: Genmab Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial | New data showed that rinatabart sesutecan (Rina-S) 100 mg/m2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), and median duration of response... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 2,962 | -2,89 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update | Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September... ► Artikel lesen | |
| BEONE MEDICINES LTD ADR | 226,00 | +0,89 % | BeOne Medicines Ltd.: BeOne Medicines präsentiert vielversprechende klinische Daten für zwei neuartige Brustkrebstherapien auf der ASCO 2025 | Vorläufige Ergebnisse unterstreichen die Antitumoraktivität und das günstige Sicherheitsprofil sowohl des B7-H4-gerichteten ADC als auch des CDK2-Inhibitors Die Daten unterstreichen die Stärke... ► Artikel lesen | |
| SINO BIOPHARM | 0,485 | -2,94 % | Aktie von Sino Biopharmaceutical: Kurs mit wenig Bewegung (0,485 €) | Am Aktienmarkt ist die Sino Biopharmaceutical-Aktie zur Stunde unauffällig. Die Aktie notiert derzeit bei 0,485 Euro. Kaum auffällig ist gegenwärtig an der Börse der Kurs von Sino Biopharmaceutical.... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,800 | -100,00 % | Moleculin Biotech, Inc.: Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) | Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy Responders (Stable Disease or Partial Response) after 2 cycles of Annamycin showed improvement... ► Artikel lesen | |
| VERICEL | 37,600 | -2,08 % | Canaccord Genuity reiterates Buy rating on Vericel stock with $61 target | ||
| SENSEI BIOTHERAPEUTICS | 0,310 | -0,32 % | H.C. Wainwright stuft Sensei Biotherapeutics-Aktie mit "Kaufen" ein | ||
| MUSTGROW BIOLOGICS | 0,542 | -5,90 % | MustGrow Biologics Corp.: MustGrow Announces Record Q1-2025 Results: $3.8 Million Revenue, 14.3% Gross Profit Margin, $4.4 Million in Cash and Inventory | Register/View Here: https://us02web.zoom.us/webinar/register/6217478678603/WN_h8uMVWINQsmS3HWF8K59WgPlease join/register at least 5 minutes prior to the call.Questions emailed to info@mustgrow.ca will... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,360 | -100,00 % | BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders ... | DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical... ► Artikel lesen | |
| ZAI LAB LTD ADR | 33,200 | -0,60 % | Zai Lab Limited: Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting | TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for... ► Artikel lesen | |
| REGENXBIO | 8,300 | -1,78 % | REGENXBIO Inc.: Regenxbio Reports New Positive Functional Data From Phase I/ii Affinity Duchenne Trial Of Rgx-202 | RGX-202 demonstrating consistent evidence of positively changing disease trajectory for Duchenne
All dose level 2 participants exceeded external natural history controls on all... ► Artikel lesen | |
| AKEBIA | 3,498 | +0,52 % | Akebia Therapeutics, Inc.: Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology | CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,420 | -2,33 % | CSTONE PHARMA-B (02616): PROPOSALS FOR GENERAL MANDATES TO ISSUE AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS, RE-APPOINTMENT OF AUDITOR AND ... |
Das Unternehmen VIVA BIOTECH HOLDINGS kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,202 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.